{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:17:36Z","timestamp":1776493056052,"version":"3.51.2"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bbrc.2021.05.049","type":"journal-article","created":{"date-parts":[[2021,5,23]],"date-time":"2021-05-23T22:21:50Z","timestamp":1621808510000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Targeting NF-\u03baB\u2013dependent alkaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells"],"prefix":"10.1016","volume":"562","author":[{"given":"Shan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1903-6180","authenticated-orcid":false,"given":"Daolin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.05.049_bib1","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bbrc.2021.05.049_bib2","article-title":"Has drug repurposing fulfilled its promise in acute myeloid leukaemia?","volume":"9","author":"Valli","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.bbrc.2021.05.049_bib3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2021.05.049_bib4","doi-asserted-by":"crossref","first-page":"106314","DOI":"10.1016\/j.leukres.2020.106314","article-title":"Venetoclax combination therapy in relapsed\/refractory acute myeloid leukemia: a single institution experience","volume":"90","author":"Gaut","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbrc.2021.05.049_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbrc.2021.05.049_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","article-title":"The molecular machinery of regulated cell death","volume":"29","author":"Tang","year":"2019","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2021.05.049_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bbrc.2021.05.049_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2021.05.049_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2021.05.049_bib10","series-title":"Alkaliptosis: a New Weapon for Cancer Therapy","author":"Liu","year":"2019"},{"key":"10.1016\/j.bbrc.2021.05.049_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-020-07469-x","article-title":"Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine","volume":"20","author":"Nishi","year":"2020","journal-title":"BMC Canc."},{"key":"10.1016\/j.bbrc.2021.05.049_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Canc."},{"key":"10.1016\/j.bbrc.2021.05.049_bib13","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1073\/pnas.96.16.9136","article-title":"NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1\/A1 is required for CD40 survival signaling in B lymphocytes","volume":"96","author":"Lee","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.05.049_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1476-4598-9-182","article-title":"NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells","volume":"9","author":"Parrondo","year":"2010","journal-title":"Mol. Canc."},{"key":"10.1016\/j.bbrc.2021.05.049_bib15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2017.12.004","article-title":"JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice","volume":"154","author":"Song","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2021.05.049_bib16","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2017.07.036","article-title":"Inhibition of Aurora kinase A induces necroptosis in pancreatic carcinoma","volume":"153","author":"Xie","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrc.2021.05.049_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","article-title":"HMGB1 in health and disease","volume":"40","author":"Kang","year":"2014","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.bbrc.2021.05.049_bib18","doi-asserted-by":"crossref","first-page":"101251","DOI":"10.1016\/j.beha.2021.101251","article-title":"Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax","volume":"34","author":"Konopleva","year":"2021","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.bbrc.2021.05.049_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/13543784.2020.1789588","article-title":"Enhancing venetoclax activity in hematological malignancies","volume":"29","author":"Satta","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2021.05.049_bib20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2021.05.049_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2021.05.049_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2021.05.049_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.trecan.2020.04.003","article-title":"NF-kappaB in the new era of cancer therapy","volume":"6","author":"Eluard","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbrc.2021.05.049_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/genes9010024","article-title":"NF-kappaB: two sides of the same coin","volume":"9","author":"Pires","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bbrc.2021.05.049_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/10799893.2018.1436561","article-title":"JTC-801 exerts anti-proliferative effects in human osteosarcoma cells by inducing apoptosis","volume":"38","author":"Zheng","year":"2018","journal-title":"J.\u00a0Recept. Signal Transduct. Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21008202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21008202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:06:18Z","timestamp":1757765178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21008202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":25,"alternative-id":["S0006291X21008202"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.049","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting NF-\u03baB\u2013dependent alkaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}